BUSINESSDESK: Genesis Research and Development, the unprofitable developer of gene silencing technology, has placed 9.1 million shares, equivalent to 20% of its existing capital, to Delight Grace, a British Virgin Islands-registered firm.
The shares were sold at 1 cent apiece, less than half the 2.5 cents they last traded at on June 29, raising $91,000.
In notes for discussion at the annual meeting last month, the company said there were “very tight market conditions for funding biotech” and a low share price meant any placement “will only raise a small amount”.
In March, the company told NZX Market Supervision that it was “able to pay its debts as they fall due and continues to be solvent”.
The statement was in response to a query from the regulator which said a shareholder had complained the company was not solvent.
UBNZ Asset Holdings, which was associated with the failed bid for the Crafar Farms, emerged last year with a 16% holding in Genesis.
The research firm is trying to negotiate a "reverse takeover" of Mariposa Health, an unlisted Australia medical researcher.
Genesis shares traded as high as $7.55 in 2001.
This article is tagged with the following keywords. Find out more about MyNBR Tags
- Cert warns 'Krack' eavesdropping vulnerability affects nearly all wi-fi devices
- Georgian billionaire sues Credit Suisse in New Zealand
- NZ has ‘little to offer’ EU in upcoming trade negotiations
- Former MediaWorks manager fails in post-restructure employment claim
- GeoOp quits planned ASX IPO, gets more shareholder funding
Most listened to
- MediaWorks has won a case against a former sales manager, Victoria Young reports
- Security expert Daniel Ayers on the 'Krack' wi-fi vulnerability scare
- NZ Beef and Lamb chairman James Parsons on what an NZ/EU FTA would mean for the beef sector
- Retirement expert Barry LaValley on misconceptions of your "golden years"
- NBR Radio: The best interviews, with Grant Walker — updated daily